IMMUNE THROMBOCYTOPENIA (ITP)

This study tests a new drug called budoprutug in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have very low platelet counts despite prior treatments. The main goal is to check safet…

This early-stage study tests a new drug called RAY121 in people with six different immune system diseases, including antiphospholipid syndrome and bullous pemphigoid. The main goal is to check safety and how the body processes the drug. About 144 adults will take part to see if t…

This study tests a medicine called V-IMMUNE® (human immunoglobulin given through a vein) to see if it can safely raise platelet counts in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. About 31 adults and…

This study tests an experimental drug called DZD8586 in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed at least one prior treatment and have very low platelet counts.…

This study tests whether adding teriflunomide to high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. About 132 participants will rece…

This early-phase study tests a new treatment called BZE2204 for people with severe autoimmune diseases like lupus, myositis, and ITP that haven't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune s…

This study tests a new drug called CM336 for people with certain blood disorders (like low platelets or anemia) that have come back or not responded to other treatments. The drug works by helping the immune system stop attacking the body's own blood cells. About 158 adults will t…

This study tests an IV medicine called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels.…

This study tests an oral drug called pirtobrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The first phase checks safety and side effects, while the second compares different doses to a placebo. …